Clinic
Orlando Health, INC.
Orlando Health, INC. was paid $105.45M by Medicaid between Jan 2018 and Dec 2024, across 658 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoORLANDO HEALTH, INC.
ORLANDO, FL 32806
ORLANDO, FL 32806
33aNPI1184709057assigned 10/26/2006
33bProvider typeEnd-Stage Renal Disease (ESRD) Treatment Clinic/Center
28Total paid$105.45M
24GClaims3,322,658
24DCodes billed658
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other End-Stage Renal Disease (ESRD) Treatment Clinic/Center providers in Florida
Rank by total paid#1 of 463
Median peer was paid$4.30M
This provider vs. median25×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 201,272 | $4.88M | |
| 2019 | 577,912 | $18.27M | |
| 2020 | 498,904 | $12.75M | |
| 2021 | 746,530 | $21.58M | |
| 2022 | 739,272 | $23.77M | |
| 2023 | 394,534 | $16.69M | |
| 2024incomplete | 164,234 | $7.52M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 222,941 | 204,104 | $21.59M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 180,019 | 152,203 | $17.31M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 4.7% | 42,611 | 12,771 | $4.96M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.3% | 48,671 | 41,848 | $4.58M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.8% | 69,201 | 20,685 | $4.01M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 45,093 | 42,281 | $3.92M |
| 80053 | Comprehensive metabolic panel | 3.1% | 150,244 | 121,143 | $3.29M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 35,202 | 28,220 | $2.19M |
| 36415 | Collection of venous blood by venipuncture | 1.6% | 157,171 | 125,046 | $1.66M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 11,594 | 10,120 | $1.62M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.5% | 34,526 | 10,640 | $1.56M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 10,363 | 9,059 | $1.18M |
646 more codes
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 613 | $1.05M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 14,120 | $1.02M |
| 59025 | Fetal non-stress test | <1% | 25,524 | $1.02M |
| 54161 | <1% | 1,190 | $960K | |
| 81003 | <1% | 87,827 | $947K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 8,676 | $872K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 11,679 | $855K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 2,700 | $855K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 16,844 | $838K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,035 | $823K |
| A0434 | Specialty care transport (sct) | <1% | 6,641 | $768K |
| 84703 | <1% | 47,446 | $758K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 18,823 | $742K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 6,016 | $635K |
| G0378 | Hospital observation service, per hour | <1% | 49,735 | $633K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 6,913 | $620K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 39,429 | $602K |
| 93304 | <1% | 1,824 | $586K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 37,844 | $508K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 57,013 | $502K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 43,279 | $485K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 4,956 | $485K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 26,925 | $469K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 5,436 | $468K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 944 | $449K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 3,121 | $439K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 24,113 | $401K |
| 82962 | <1% | 28,065 | $392K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 72,199 | $385K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,238 | $374K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,893 | $373K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 17,656 | $318K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 163,044 | $309K |
| 95715 | <1% | 1,183 | $288K | |
| 77386 | <1% | 2,156 | $284K | |
| 77336 | <1% | 1,858 | $282K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 4,104 | $270K |
| 76770 | <1% | 3,042 | $263K | |
| 87631 | <1% | 18,988 | $263K | |
| 97161 | <1% | 2,767 | $261K | |
| 92567 | <1% | 6,915 | $259K | |
| 97162 | <1% | 3,706 | $258K | |
| 93308 | <1% | 1,279 | $257K | |
| 71045 | Radiologic examination, chest; single view | <1% | 51,079 | $251K |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 1,612 | $248K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,337 | $244K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 8,916 | $238K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,384 | $229K |
| 92587 | <1% | 5,627 | $210K | |
| 58661 | <1% | 175 | $203K | |
| 74019 | <1% | 8,499 | $197K | |
| 76775 | <1% | 3,154 | $194K | |
| 92523 | <1% | 1,872 | $190K | |
| 83986 | <1% | 2,208 | $184K | |
| 84702 | <1% | 11,342 | $174K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 9,841 | $173K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 56,319 | $165K |
| 01999 | <1% | 9,644 | $164K | |
| 97597 | <1% | 3,323 | $159K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,946 | $157K |
| 36430 | <1% | 1,787 | $156K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14,151 | $144K |
| 86850 | <1% | 16,592 | $144K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13,272 | $143K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 4,296 | $136K |
| 85027 | <1% | 43,169 | $135K | |
| 93017 | <1% | 4,536 | $134K | |
| 95812 | <1% | 594 | $134K | |
| 97163 | <1% | 1,394 | $131K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,824 | $130K |
| 81001 | <1% | 46,188 | $124K | |
| 97165 | <1% | 1,908 | $120K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 7,019 | $119K |
| 84484 | <1% | 46,468 | $119K | |
| 92526 | <1% | 3,956 | $115K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 406 | $114K |
| 70491 | <1% | 1,063 | $111K | |
| 97166 | <1% | 1,171 | $110K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 802 | $110K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,139 | $106K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 414 | $106K |
| 82330 | <1% | 3,949 | $105K | |
| 74018 | <1% | 5,446 | $103K | |
| 97010 | <1% | 2,560 | $102K | |
| 76801 | <1% | 7,048 | $101K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,541 | $100K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 485 | $100K |
| 11045 | <1% | 640 | $98K | |
| 83735 | <1% | 37,770 | $97K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,794 | $97K |
| 97116 | <1% | 4,977 | $96K | |
| 73562 | <1% | 5,347 | $90K | |
| 93325 | <1% | 7,807 | $89K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 373 | $87K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 17,672 | $86K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,757 | $85K |
| 74230 | <1% | 1,086 | $85K | |
| 73630 | <1% | 4,642 | $84K | |
| 96367 | <1% | 2,482 | $84K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,693 | $83K |
| 74174 | <1% | 1,288 | $81K | |
| 76830 | Ultrasound, transvaginal | <1% | 5,611 | $80K |
| 73130 | <1% | 3,836 | $78K | |
| 86900 | <1% | 20,238 | $78K | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 261 | $77K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 9,243 | $77K |
| 44970 | <1% | 56 | $75K | |
| 77300 | <1% | 233 | $72K | |
| 73610 | <1% | 4,279 | $71K | |
| 87486 | <1% | 4,316 | $71K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,072 | $67K |
| 97167 | <1% | 1,011 | $65K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 6,208 | $64K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 4,402 | $64K |
| 93971 | <1% | 3,474 | $63K | |
| 95782 | <1% | 170 | $62K | |
| 85610 | <1% | 13,560 | $61K | |
| 73030 | <1% | 3,629 | $60K | |
| 82570 | <1% | 5,091 | $60K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 579 | $60K |
| 96401 | <1% | 839 | $59K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 439 | $57K |
| 77334 | <1% | 415 | $57K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 764 | $57K |
| 87420 | <1% | 774 | $56K | |
| 93970 | <1% | 2,010 | $55K | |
| 76870 | <1% | 1,324 | $54K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 22,583 | $54K |
| 12011 | <1% | 1,706 | $53K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,339 | $53K |
| 70496 | <1% | 263 | $53K | |
| 77387 | <1% | 95 | $52K | |
| 87480 | <1% | 12,016 | $52K | |
| 74240 | <1% | 641 | $52K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,094 | $52K |
| 76536 | <1% | 988 | $51K | |
| 95700 | <1% | 1,181 | $51K | |
| 95819 | <1% | 795 | $51K | |
| 10060 | <1% | 1,114 | $51K | |
| C1769 | Guide wire | <1% | 2,498 | $51K |
| 92579 | <1% | 3,408 | $50K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,149 | $49K |
| 83690 | <1% | 28,254 | $48K | |
| 73110 | <1% | 2,886 | $48K | |
| 76885 | <1% | 539 | $47K | |
| 92557 | <1% | 708 | $46K | |
| 87070 | <1% | 3,416 | $45K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,577 | $45K |
| 87081 | <1% | 3,597 | $44K | |
| 73090 | <1% | 2,530 | $42K | |
| 82247 | <1% | 3,111 | $42K | |
| 12001 | <1% | 1,291 | $42K | |
| 96376 | <1% | 11,203 | $41K | |
| 20680 | <1% | 75 | $40K | |
| 73140 | <1% | 1,266 | $40K | |
| 36591 | <1% | 2,441 | $39K | |
| 87077 | <1% | 3,823 | $38K | |
| 16020 | <1% | 449 | $38K | |
| 82728 | <1% | 8,961 | $38K | |
| 73080 | <1% | 1,932 | $37K | |
| Q0114 | Fern test | <1% | 2,401 | $37K |
| 96402 | <1% | 300 | $36K | |
| 87634 | <1% | 1,030 | $36K | |
| 92610 | <1% | 610 | $35K | |
| 73590 | <1% | 2,770 | $34K | |
| 72141 | <1% | 645 | $34K | |
| 93356 | <1% | 561 | $34K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,703 | $34K |
| 74455 | <1% | 276 | $33K | |
| 82657 | <1% | 2,461 | $33K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 17,606 | $33K |
| 70486 | <1% | 1,940 | $33K | |
| 81025 | <1% | 23,020 | $32K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,633 | $31K |
| 83880 | <1% | 7,574 | $30K | |
| 80061 | Lipid panel | <1% | 13,437 | $30K |
| 99152 | <1% | 2,478 | $30K | |
| 87510 | <1% | 12,009 | $30K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,681 | $29K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 559 | $29K |
| 76825 | <1% | 168 | $28K | |
| 86901 | <1% | 20,221 | $28K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,417 | $28K |
| 99153 | Mod sedat endo service >5yrs | <1% | 2,229 | $27K |
| 93296 | <1% | 2,201 | $26K | |
| 85730 | <1% | 8,239 | $26K | |
| 82565 | <1% | 3,186 | $26K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,871 | $26K |
| 96523 | <1% | 1,859 | $25K | |
| 93225 | <1% | 1,701 | $25K | |
| 01922 | <1% | 365 | $25K | |
| 87505 | <1% | 795 | $24K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 71 | $24K |
| 72100 | <1% | 2,327 | $24K | |
| 93280 | <1% | 1,675 | $23K | |
| 96415 | <1% | 1,166 | $23K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 827 | $22K |
| 86592 | <1% | 4,325 | $22K | |
| 92555 | <1% | 361 | $21K | |
| 85014 | <1% | 2,849 | $21K | |
| 87660 | <1% | 12,064 | $21K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 13,329 | $21K |
| 88307 | <1% | 847 | $21K | |
| 86140 | <1% | 8,753 | $20K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,403 | $20K |
| 90686 | <1% | 368 | $20K | |
| 70250 | <1% | 375 | $19K | |
| 71250 | <1% | 926 | $19K | |
| 86480 | <1% | 799 | $19K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 161 | $19K |
| 93226 | <1% | 1,212 | $18K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 3,513 | $18K |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 262 | $18K |
| 12002 | <1% | 536 | $18K | |
| 84132 | <1% | 3,227 | $18K | |
| 95951 | <1% | 232 | $18K | |
| 72170 | <1% | 2,569 | $18K | |
| 73552 | <1% | 1,660 | $18K | |
| 72131 | <1% | 3,077 | $17K | |
| 87040 | <1% | 5,557 | $17K | |
| 92552 | <1% | 336 | $17K | |
| V5011 | Fitting/orientation/checking of hearing aid | <1% | 504 | $17K |
| 83550 | <1% | 7,015 | $17K | |
| 92652 | <1% | 350 | $17K | |
| 88304 | <1% | 1,286 | $17K | |
| 73502 | <1% | 1,449 | $17K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 75 | $16K |
| 72040 | <1% | 892 | $16K | |
| 82550 | <1% | 4,475 | $16K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,554 | $16K |
| 85379 | <1% | 6,386 | $16K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 3,045 | $16K |
| 93880 | <1% | 826 | $16K | |
| 83605 | <1% | 7,006 | $15K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 937 | $15K |
| 97542 | <1% | 197 | $15K | |
| 96409 | <1% | 1,428 | $15K | |
| 82378 | <1% | 1,929 | $14K | |
| 76010 | <1% | 339 | $14K | |
| 96368 | <1% | 523 | $14K | |
| 70360 | <1% | 544 | $14K | |
| 92585 | <1% | 338 | $14K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,042 | $13K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 12,335 | $13K |
| 82784 | <1% | 1,929 | $13K | |
| 73060 | <1% | 1,070 | $13K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,144 | $13K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,379 | $13K |
| 10061 | <1% | 285 | $12K | |
| 93798 | <1% | 232 | $12K | |
| 93282 | <1% | 585 | $11K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 2,930 | $11K |
| 70543 | <1% | 149 | $11K | |
| 76641 | <1% | 239 | $11K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,608 | $11K |
| 84439 | <1% | 7,800 | $11K | |
| 24640 | <1% | 39 | $11K | |
| 80074 | <1% | 1,032 | $11K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,950 | $10K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 350 | $10K |
| 86308 | <1% | 1,688 | $10K | |
| 87507 | <1% | 309 | $10K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14,791 | $10K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,112 | $10K |
| 72197 | <1% | 61 | $10K | |
| 87529 | <1% | 781 | $10K | |
| 51600 | <1% | 273 | $10K | |
| A6454 | Self-adherent bandage, elastic, non-knitted/non-woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 94 | $10K |
| 96450 | <1% | 46 | $10K | |
| 72128 | <1% | 2,227 | $10K | |
| 85018 | <1% | 3,607 | $9K | |
| 93299 | <1% | 418 | $9K | |
| 87186 | <1% | 7,337 | $9K | |
| 82024 | <1% | 595 | $9K | |
| 83540 | <1% | 7,536 | $9K | |
| 86923 | <1% | 804 | $9K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 36 | $9K |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 710 | $9K |
| 70498 | <1% | 252 | $9K | |
| 93886 | <1% | 100 | $9K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 78 | $9K |
| 77301 | <1% | 44 | $8K | |
| 84100 | <1% | 9,680 | $8K | |
| 93321 | <1% | 2,970 | $8K | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 3,189 | $8K |
| 83020 | <1% | 3,355 | $8K | |
| A6261 | Wound filler, gel/paste, per fluid ounce, not otherwise specified | <1% | 285 | $8K |
| 85652 | <1% | 8,180 | $8K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 348 | $7K |
| 84145 | <1% | 1,800 | $7K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 37 | $7K |
| A6198 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 48 sq. in., each dressing | <1% | 156 | $7K |
| 86922 | <1% | 464 | $7K | |
| 93298 | <1% | 842 | $7K | |
| 77412 | <1% | 63 | $7K | |
| 90715 | <1% | 2,368 | $7K | |
| 83970 | <1% | 1,794 | $7K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 17 | $7K |
| 87210 | <1% | 2,178 | $7K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,885 | $6K |
| 87340 | <1% | 4,084 | $6K | |
| 86003 | <1% | 964 | $6K | |
| 88185 | <1% | 139 | $6K | |
| 86902 | <1% | 1,009 | $6K | |
| 70544 | <1% | 246 | $6K | |
| 36592 | <1% | 712 | $6K | |
| 86870 | <1% | 447 | $6K | |
| 84295 | <1% | 1,551 | $6K | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 99 | $6K |
| 86300 | <1% | 837 | $6K | |
| 82805 | <1% | 2,093 | $6K | |
| 82248 | <1% | 5,556 | $6K | |
| 85244 | <1% | 223 | $6K | |
| 96417 | <1% | 1,320 | $5K | |
| 00300 | <1% | 127 | $5K | |
| 78451 | <1% | 45 | $5K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 380 | $5K |
| 00210 | <1% | 71 | $5K | |
| 84520 | <1% | 1,428 | $5K | |
| 29581 | <1% | 120 | $5K | |
| 82607 | <1% | 4,118 | $5K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 392 | $5K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 190 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 10,766 | $5K |
| 87581 | <1% | 4,312 | $5K | |
| 82150 | <1% | 1,001 | $5K | |
| 87641 | <1% | 383 | $5K | |
| 85045 | <1% | 10,573 | $5K | |
| 82947 | <1% | 1,494 | $4K | |
| 29125 | <1% | 712 | $4K | |
| 43762 | <1% | 47 | $4K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 165 | $4K |
| 73660 | <1% | 187 | $4K | |
| 92586 | <1% | 51 | $4K | |
| 86787 | <1% | 783 | $4K | |
| 74021 | <1% | 328 | $4K | |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 254 | $4K |
| 85245 | <1% | 293 | $4K | |
| 83520 | <1% | 705 | $4K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,947 | $4K |
| 87205 | <1% | 2,814 | $4K | |
| 82435 | <1% | 1,239 | $4K | |
| 85384 | <1% | 2,269 | $4K | |
| 94060 | <1% | 36 | $4K | |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | <1% | 87 | $4K |
| 82785 | <1% | 1,002 | $3K | |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | <1% | 17 | $3K |
| 87147 | <1% | 1,760 | $3K | |
| 36410 | <1% | 229 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,554 | $3K |
| 88342 | <1% | 1,132 | $3K | |
| 73000 | <1% | 68 | $3K | |
| 36593 | <1% | 98 | $3K | |
| 82803 | <1% | 257 | $3K | |
| 73560 | <1% | 387 | $3K | |
| 73521 | <1% | 68 | $3K | |
| 76818 | <1% | 60 | $3K | |
| 76377 | <1% | 292 | $3K | |
| 93270 | <1% | 64 | $3K | |
| 59320 | <1% | 13 | $3K | |
| 93283 | <1% | 158 | $3K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,503 | $2K |
| 83021 | <1% | 3,351 | $2K | |
| 00920 | <1% | 876 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,029 | $2K |
| 83615 | <1% | 3,767 | $2K | |
| 82746 | <1% | 2,654 | $2K | |
| 72158 | <1% | 100 | $2K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 433 | $2K |
| 93284 | <1% | 203 | $2K | |
| 86360 | <1% | 690 | $2K | |
| 71101 | <1% | 150 | $2K | |
| 86920 | <1% | 1,489 | $2K | |
| 87497 | <1% | 125 | $2K | |
| 72156 | <1% | 65 | $2K | |
| 72146 | <1% | 304 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 577 | $2K |
| 92556 | <1% | 188 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,095 | $2K |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 168 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,256 | $2K |
| A0425 | Ground mileage, per statute mile | <1% | 1,310 | $2K |
| 80197 | <1% | 1,636 | $2K | |
| 85246 | <1% | 557 | $2K | |
| 76000 | <1% | 75 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,909 | $2K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,940 | $2K |
| 84157 | <1% | 608 | $2K | |
| 77072 | <1% | 47 | $2K | |
| 86706 | <1% | 1,012 | $2K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 333 | $2K |
| 76800 | <1% | 20 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 531 | $2K |
| 75571 | <1% | 104 | $2K | |
| 99151 | <1% | 281 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 517 | $2K |
| 00500 | <1% | 79 | $2K | |
| 82575 | <1% | 156 | $2K | |
| 82670 | <1% | 178 | $2K | |
| 69200 | <1% | 33 | $2K | |
| 92611 | <1% | 850 | $2K | |
| 99219 | <1% | 1,025 | $1K | |
| 00731 | <1% | 331 | $1K | |
| 85240 | <1% | 401 | $1K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 103 | $1K |
| 85660 | <1% | 4,038 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 649 | $1K |
| 36000 | <1% | 123 | $1K | |
| 86038 | <1% | 669 | $1K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 112 | $1K |
| 87075 | <1% | 743 | $1K | |
| 90378 | <1% | 43 | $1K | |
| 99218 | <1% | 488 | $1K | |
| 87015 | <1% | 41 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 868 | $1K |
| 86803 | <1% | 1,984 | $1K | |
| 97032 | <1% | 64 | $1K | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 162 | $1K |
| 82140 | <1% | 417 | $1K | |
| 92582 | <1% | 146 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13,861 | $1K |
| 83655 | <1% | 304 | $1K | |
| 96040 | <1% | 14 | $1K | |
| 00320 | <1% | 217 | $1K | |
| OP259 | <1% | 130 | $1K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 134 | $1K |
| 84156 | <1% | 5,237 | $1K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 396 | $1K |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 95 | $1K |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | <1% | 95 | $1K |
| 82272 | <1% | 25 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 44 | $1K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,118 | $1K |
| 72070 | <1% | 71 | $1K | |
| 80164 | <1% | 257 | $1K | |
| 96411 | <1% | 704 | $1K | |
| 86762 | <1% | 2,200 | $1K | |
| 76642 | <1% | 80 | $983.06 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,237 | $980.91 |
| 80076 | <1% | 267 | $913.75 | |
| 87176 | <1% | 2,371 | $899.73 | |
| 93320 | <1% | 2,507 | $897.27 | |
| 77066 | Tomosynthesis, mammo | <1% | 28 | $874.69 |
| 87799 | <1% | 182 | $873.20 | |
| 82950 | <1% | 447 | $868.45 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 60 | $850.33 |
| 86364 | <1% | 185 | $834.54 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 279 | $832.61 |
| 77338 | <1% | 47 | $809.14 | |
| 86359 | <1% | 693 | $793.78 | |
| 84550 | <1% | 1,325 | $772.82 | |
| 87449 | <1% | 145 | $758.73 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 403 | $730.23 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 282 | $709.21 |
| J9370 | Vincristine sulfate, 1 mg | <1% | 388 | $696.88 |
| 87536 | <1% | 56 | $688.67 | |
| 51701 | <1% | 1,178 | $673.13 | |
| 01462 | <1% | 125 | $659.25 | |
| 76376 | <1% | 15 | $657.38 | |
| 84146 | <1% | 278 | $651.53 | |
| 83001 | <1% | 457 | $648.14 | |
| 84403 | <1% | 538 | $644.90 | |
| 12013 | <1% | 32 | $595.89 | |
| 84311 | <1% | 2,533 | $588.80 | |
| 76827 | <1% | 207 | $578.36 | |
| 00790 | <1% | 24 | $573.89 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,254 | $570.42 |
| 85576 | <1% | 254 | $558.40 | |
| 01965 | <1% | 42 | $551.90 | |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 37 | $547.36 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 666 | $539.83 |
| A0390 | Als mileage (per mile) | <1% | 4,598 | $527.42 |
| J1815 | Injection, insulin, per 5 units | <1% | 395 | $512.55 |
| 83516 | <1% | 444 | $510.65 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 372 | $504.37 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 36 | $500.77 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 36 | $500.77 |
| 0450 | Emergency room services | <1% | 14 | $480.98 |
| 73600 | <1% | 32 | $476.10 | |
| 00630 | <1% | 12 | $472.02 | |
| 72157 | <1% | 39 | $463.90 | |
| 72050 | <1% | 13 | $460.42 | |
| 90714 | <1% | 534 | $455.60 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 561 | $455.09 |
| 49465 | <1% | 168 | $454.31 | |
| 88313 | <1% | 136 | $453.30 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 319 | $453.25 |
| 86769 | <1% | 158 | $451.66 | |
| 00520 | <1% | 13 | $430.57 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,501 | $412.63 |
| 97760 | <1% | 14 | $408.67 | |
| 77080 | <1% | 22 | $400.95 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 37 | $391.38 |
| 82043 | <1% | 815 | $374.81 | |
| 83525 | <1% | 371 | $354.78 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 251 | $333.69 |
| 95709 | <1% | 16 | $328.73 | |
| 94644 | <1% | 82 | $324.02 | |
| 81479 | Unlisted molecular pathology procedure | <1% | 12 | $303.84 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 518 | $302.59 |
| 86880 | <1% | 708 | $300.02 | |
| 93285 | <1% | 30 | $296.46 | |
| 88341 | <1% | 155 | $287.37 | |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 36 | $281.29 |
| 72072 | <1% | 12 | $278.50 | |
| 88184 | <1% | 141 | $278.16 | |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 223 | $258.99 |
| 84481 | <1% | 273 | $253.80 | |
| 89050 | <1% | 292 | $242.49 | |
| OP251 | <1% | 21 | $235.51 | |
| 86355 | <1% | 84 | $228.88 | |
| 84460 | <1% | 304 | $224.09 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,386 | $218.52 |
| 86665 | <1% | 25 | $218.48 | |
| 82379 | <1% | 465 | $213.93 | |
| 87071 | <1% | 291 | $203.24 | |
| 80050 | General health panel | <1% | 66 | $200.21 |
| 86905 | <1% | 20 | $185.01 | |
| 82105 | <1% | 203 | $184.77 | |
| 82533 | <1% | 130 | $177.86 | |
| 95886 | <1% | 58 | $176.39 | |
| 86376 | <1% | 645 | $175.93 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,207 | $175.70 |
| 82010 | <1% | 530 | $174.16 | |
| 86235 | <1% | 16 | $147.86 | |
| 88360 | <1% | 57 | $133.56 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 199 | $129.99 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 134 | $123.20 |
| 86160 | <1% | 32 | $122.81 | |
| 76942 | <1% | 16 | $119.24 | |
| 86304 | <1% | 57 | $118.65 | |
| 82977 | <1% | 884 | $116.47 | |
| 84436 | <1% | 78 | $113.50 | |
| 86357 | <1% | 84 | $109.96 | |
| 86147 | <1% | 12 | $104.08 | |
| 88142 | <1% | 12 | $92.72 | |
| 82951 | <1% | 12 | $92.16 | |
| 86800 | <1% | 184 | $88.45 | |
| 82945 | <1% | 348 | $78.10 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 281 | $69.25 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 530 | $69.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,106 | $66.67 |
| 87324 | <1% | 73 | $64.23 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 30 | $62.74 |
| 85230 | <1% | 32 | $61.03 | |
| 86301 | <1% | 18 | $56.34 | |
| 89230 | <1% | 21 | $55.08 | |
| 0279U | <1% | 13 | $49.78 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 68 | $48.96 |
| 96167 | <1% | 43 | $48.70 | |
| 73070 | <1% | 14 | $41.18 | |
| 84480 | <1% | 291 | $39.89 | |
| 85397 | <1% | 41 | $39.84 | |
| 87102 | <1% | 225 | $39.12 | |
| 84450 | <1% | 134 | $38.34 | |
| 87181 | <1% | 66 | $34.80 | |
| 82438 | <1% | 69 | $29.69 | |
| 84305 | <1% | 83 | $28.85 | |
| 94729 | <1% | 52 | $26.98 | |
| 86765 | <1% | 565 | $26.02 | |
| 87073 | <1% | 276 | $25.34 | |
| 85670 | <1% | 26 | $24.72 | |
| A6210 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing | <1% | 30 | $23.54 |
| 87653 | <1% | 17 | $21.02 | |
| 85130 | <1% | 75 | $20.24 | |
| 83883 | <1% | 16 | $19.83 | |
| 83002 | <1% | 357 | $19.62 | |
| 86735 | <1% | 567 | $18.92 | |
| 87116 | <1% | 78 | $17.54 | |
| 84630 | <1% | 71 | $11.76 | |
| 88108 | <1% | 141 | $8.12 | |
| 84165 | <1% | 29 | $6.68 | |
| 84478 | <1% | 185 | $6.10 | |
| 84133 | <1% | 12 | $4.69 | |
| 01990 | <1% | 67 | $4.06 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 56 | $4.06 |
| 29505 | <1% | 15 | $3.87 | |
| 87206 | <1% | 75 | $3.87 | |
| 86431 | <1% | 46 | $3.36 | |
| 86225 | <1% | 30 | $3.36 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 770 | $3.26 |
| 73100 | <1% | 13 | $2.79 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 750 | $1.50 |
| 84155 | <1% | 51 | $1.48 | |
| 29515 | 0% | 90 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 452 | $0.00 |
| 01820 | 0% | 99 | $0.00 | |
| 00940 | 0% | 319 | $0.00 | |
| 89051 | 0% | 15 | $0.00 | |
| 00840 | 0% | 63 | $0.00 | |
| 76937 | 0% | 49 | $0.00 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 0% | 233 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 13 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 69 | $0.00 |
| 82652 | 0% | 16 | $0.00 | |
| 86663 | 0% | 26 | $0.00 | |
| 84112 | 0% | 17 | $0.00 | |
| 88302 | 0% | 74 | $0.00 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 79 | $0.00 |
| 58670 | 0% | 19 | $0.00 | |
| 00750 | 0% | 31 | $0.00 | |
| 85347 | 0% | 58 | $0.00 | |
| 97803 | 0% | 26 | $0.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 14 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 16 | $0.00 |
| 90461 | 0% | 13 | $0.00 | |
| 86664 | 0% | 25 | $0.00 | |
| 51798 | 0% | 57 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 1,438 | $0.00 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 30 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 142 | $0.00 |
| 74183 | 0% | 13 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 13 | $0.00 |
| 97802 | 0% | 26 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 218 | $0.00 |
| 84255 | 0% | 33 | $0.00 | |
| 84160 | 0% | 18 | $0.00 | |
| 80177 | 0% | 16 | $0.00 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 292 | $0.00 |
| 84402 | 0% | 25 | $0.00 | |
| 82525 | 0% | 32 | $0.00 | |
| 84075 | 0% | 13 | $0.00 | |
| J9202 | Goserelin acetate implant, per 3.6 mg | 0% | 36 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 124 | $0.00 |
| 01710 | 0% | 35 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 33 | $0.00 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 101 | $0.00 |
| 92650 | 0% | 25 | $0.00 | |
| 84485 | 0% | 16 | $0.00 | |
| 88311 | 0% | 12 | $0.00 | |
| 81050 | 0% | 36 | $0.00 | |
| 82139 | 0% | 13 | $0.00 | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | 0% | 25 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 17 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 28 | $0.00 |
| 94660 | 0% | 14 | $0.00 | |
| 82952 | 0% | 12 | $0.00 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 30 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 40 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 17 | $0.00 |
| 84153 | 0% | 15 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 34 | $0.00 |
| 00930 | 0% | 26 | $0.00 | |
| 82040 | 0% | 13 | $0.00 | |
| 73620 | 0% | 14 | $0.00 | |
| C9250 | Human plasma fibrin sealant, vapor-heated, solvent-detergent (artiss), 2 ml | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNAPIER, MICHELE (CHIEF REVENUE OFFICIER)
| Provider | Location | Paid |
|---|---|---|
| Orlando Health Medical Group INC | Orlando, FL | $57.49M |
| South Lake Hospital, INC. | Clermont, FL | $16.88M |
| Orlando Physicians Network INC | Orlando, FL | $9.44M |
| Baptist Health Centers LLC | Talladega, AL | $6.99M |
| Baptist Health Centers, LLC | Winfield, AL | $2.15M |
| Baptist Health Centers LLC | Talladega, AL | $2.00M |
| Ohi West Medical Group, LLC | St Petersburg, FL | $1.28M |
| Orlando Regional Healthcare | Orlando, FL | $1.01M |
| Baptist Health Centers, LLC | Lincoln, AL | $988K |
| BW Physician Practices, LLC | Birmingham, AL | $967K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.